CRISPR Screen and Single-Cell Multi-Omics Identify a Novel Immune Checkpoint on Tumor-Infiltrating Regulatory T Cells
DOI:
https://doi.org/10.63808/irc.v2i1.525Keywords:
CRISPR screen, Single-cell multi-omics, Regulatory T cells, Immune checkpoint, Cancer immunotherapy, LILRB4Abstract
Tumor infiltration regulatory T cells (Tregs) mediate immune escape by highly expressing multiple inhibitory receptors, which is one of the key factors in resistance to existing immune checkpoint inhibitors. However, systematic screening of Treg-specific immune checkpoints within tumors remains lacking. This study aims to integrate CRISPR functional screening with single-cell multi-omics to identify novel immune checkpoints with selective high expression and key inhibitory functions on intratumoral Tregs. A mouse tumor model was constructed to screen candidate genes affecting tumor growth in Treg using in vivo CRISPR-Cas9 libraries; Transcription and chromatin accessibility differences between tumor-infiltrating Treg and peripheral Treg were analyzed by combining single-cell RNA sequencing (scRNA-seq) and single-cell ATAC sequencing (scATAC-seq); Candidate molecular functions were validated through conditional gene knockout mice, antibody blockade, and tumor-infiltrating lymphocyte functional experiments, and their expression and clinical relevance in human tumor samples were evaluated. Leukocyte immunoglobulin-like receptor B4 (LILRB4) was identified as a novel immune checkpoint molecule selectively highly expressed on tumor-infiltrating Tregs, with expression induced by hypoxia in the tumor microenvironment and IL-10 signaling. The intracellular ITIM motif of LILRB4 enhances Treg’s inhibitory function and stability. Conditional knockout of Lilrb4 in Tregs or use of anti-LILRB4 monoclonal antibodies can significantly reshape the tumor immune microenvironment, enhance CD8 T cell effector function, inhibit tumor growth in various mice (tumor volume reduction by about 60%), and do not induce systemic autoimmunity. Human tumor sample analysis showed that LILRB4 expression on tumor-infiltrating Treg is significantly associated with anti-PD-1 resistance and poor patient prognosis. This study systematically reveals for the first time the function and mechanism of LILRB4 as a Treg-specific immune checkpoint for tumor infiltration, providing a theoretical basis and potential drug targets for developing a new generation of tumor immunotherapies that selectively target intratumoral Tregs while preserving peripheral immune tolerance.
References
[1] Chang, C. C., Ciubotariu, R., Manavalan, J. S., et al. (2002). Tolerization of dendritic cells by T cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol, 3(3), 237-243. https://doi.org/10.1038/ni760
[2] Chen, H. M., van der Touw, W., Wang, Y. S., et al. (2018). Blocking immunoinhibitory receptor LILRB4 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Invest, 128(12), 5647-5662. https://doi.org/10.1172/JCI97570
[3] Cortez, J. T., Montauti, E., Shifrut, E., et al. (2020). CRISPR screen in regulatory T cells reveals modulators of Foxp3. Nature, 582(7812), 416-420. https://doi.org/10.1038/s41586-020-2246-4
[4] De Simone, M., Arrigoni, A., Rossetti, G., et al. (2016). Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity, 45(5), 1135-1147. https://doi.org/10.1016/j.immuni.2016.10.021
[5] Deng, M., Gui, X., Kim, J., et al. (2018). LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature, 562(7728), 605-609. https://doi.org/10.1038/s41586-018-0615-z
[6] Itagaki, F., Nakatsuka, K., Sakai, H., Endo, S., Su, M. T., & Takai, T. (2023). Fibronectin on target cells attenuates natural cytotoxicity of NK cells via myeloid immune checkpoint ILT3/LILRB4/gp49B. Int Immunol, 35(7), 339-348. https://doi.org/ 10.1093/intimm/dxad012
[7] Kim, J. M., Rasmussen, J. P., Rudensky, & A. Y. (2007). Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol, 8(2), 191-197. https://doi.org/10.1038/ni1428
[8] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med, 373(1), 23-34. https://doi.org/10.1056/NEJMoa1504030
[9] Liu, G. (2026a). The application of artificial intelligence in tumor immunotherapy: integrating multi-omics data to achieve efficacy prediction and combination strategies. Applied Artificial Intelligence Research, 2(2). https://doi.org/10.65455/q72yq328
[10] Liu, G. (2026b). Tumor microenvironment: composition, dynamic evolution, and its significance in cancer treatment. Journal of Cancer Insights, 1(1), 6. https://doi.org/10.66128/jci202601.1
[11] Liu, G., Wang, J., Zhu, J. (2026). Explainable spatial AI analyzes tumor-immune interactions to predict immunotherapy outcomes and identify new targets. Intelligent & Human Futures, 2(3), 510. https://doi.org/10.63808/ihf.v2i3.510
[12] Magnuson, A. M., Kiner, E., Ergun, A., Park, J. S., Asinovski, N., Ortiz-Lopez, A., Kilcoyne, A., Paoluzzi-Tomada, E., Weissleder, R., Mathis, D., & Benoist, C. (2018). Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types. Proc Natl Acad Sci U S A, 115(45), E10672-E10681. https://doi.org/10.1073/pnas.1810580115
[13] Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med, 378(2), 158-168. https://doi.org/10.1056/NEJMra1703481
[14] Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008). Regulatory T cells and immune tolerance. Cell, 133(5), 775-787. https://doi.org/10.1016/j.cell.2008.05.009
[15] Sharma, N., Atolagbe, O. T., Ge, Z., et al. (2021). LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med, 218(7), e20201811. https://doi.org/10.1084/jem.20201811
[16] Shifrut, E., Carnevale, J., Tobin, V., et al. (2018). Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell, 175(7), 1958-1971.e15. https://doi.org/10.1016/j.cell.2018.10.024
[17] Simpson, T. R., Li, F., Montalvo-Ortiz, W., et al. (2013). Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med, 210(9), 1695-1710. https://doi.org/10.1084/jem.20130579
[18] Tanaka, A., & Sakaguchi, S. (2017). Regulatory T cells in cancer immunotherapy. Cell Res, 27(1), 109-118. https://doi.org/10.1038/cr.2016.151
[19] Togashi, Y., Shitara, K., & Nishikawa, H. (2019). Regulatory T cells in cancer immunosuppression — implications for anticancer therapy. Nat Rev Clin Oncol, 16(6), 356-371. https://doi.org/10.1038/s41571-019-0175-7
[20] Wei, J., Long, L., Zheng, W., et al. (2019). Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature, 576(7787), 471-476. https://doi.org/10.1038/s41586-019-1821-z
[21] Wing, K., Onishi, Y., Prieto-Martin, P., et al. (2008). CTLA-4 control over Foxp3+ regulatory T cell function. Science, 322(5899), 271-275. https://doi.org/10.1126/science.1160062
[22] Zheng, C., Zheng, L., Yoo, J. K., et al. (2017). Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell, 169(7), 1342-1356.e16. https://doi.org/10.1016/j.cell.2017.05.035
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Gang Liu, Jia Wang, Liqiang An
This work is licensed under a Creative Commons Attribution 4.0 International License.